NASDAQ
10.11USD
-0.16 (-1.56%)
Dots are scored news catalysts — size = impact, color = sentiment. Tap one to read it.
Market cap
18M
P/E
—
EPS
—
Beta
-0.07
52W range
5.61-31
Day range
9.81–10.79
Open
10.79
Prev close
10.27
Volume
38.9K
Avg volume
49.1K
Dividend
0.00
IPO
1997-10-15
No scored news tagged PTN or its network in the window yet.
Show more PTN articles →Palatin Technologies, Inc., a biopharmaceutical company, develops first-in-class medicines based on molecules that modulate the activity of the melanocortin receptor system in the United States. It is developing oral small molecule PL7737 MC4R agonist in preclinical studies; long-acting peptide MC4R agonists; and Bremelanotide co-administration with Tirzepatide to treat obesity in Phase 2 trial, as well as Bremelanotide co-formulated with a PDE5i for the treatment of ED in patients not adequately responsive to PDE5i monotherapy. The company also develops PL9643 for dry eye disease and anti-inflammatory ocular indications; and oral PL8177 for the treatment inflammatory bowel diseases. Palatin Technologies, Inc. was incorporated in 1986 and is based in Monmouth Junction, New Jersey.
Daily OHLCV with SMA overlays and session pivots. Draw your levels and trendlines on it, or ask the AI analyst what the price is reacting to.
Suppliers, customers, partners and competitors, derived from what the news actually says about Palatin Technologies, Inc. — not a sector bucket. Click an edge to see the articles that established the link.
Latest scored catalyst for PTN: .
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
